Annis Gardner Whiting Capital Advisors LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Annis Gardner Whiting Capital Advisors LLC acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 100,400 shares of the biotechnology company’s stock, valued at approximately $352,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Xponance LLC lifted its position in Iovance Biotherapeutics by 19.4% in the 4th quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock worth $66,000 after buying an additional 3,950 shares during the last quarter. Raymond James Financial Inc. grew its position in Iovance Biotherapeutics by 1.4% during the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 4,618 shares during the last quarter. Orion Investment Co grew its position in Iovance Biotherapeutics by 0.3% during the fourth quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock valued at $5,069,000 after acquiring an additional 5,150 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Iovance Biotherapeutics by 37.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,290 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 5,301 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in shares of Iovance Biotherapeutics by 13.5% during the fourth quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 5,563 shares in the last quarter. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IOVA has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Iovance Biotherapeutics has an average rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $5.00 on Friday. Iovance Biotherapeutics, Inc. has a one year low of $1.76 and a one year high of $5.63. The business’s 50 day simple moving average is $4.06 and its two-hundred day simple moving average is $3.55. The stock has a market capitalization of $2.23 billion, a P/E ratio of -5.26 and a beta of 0.70.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The firm had revenue of $71.43 million during the quarter, compared to analyst estimates of $77.84 million. During the same quarter in the prior year, the firm posted ($0.36) earnings per share. The business’s quarterly revenue was up 44.9% compared to the same quarter last year. Sell-side analysts expect that Iovance Biotherapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.